[go: up one dir, main page]

MX2018005135A - Anticuerpos biespecificos anti-cgrp/anti-il-23 y usos de los mismos. - Google Patents

Anticuerpos biespecificos anti-cgrp/anti-il-23 y usos de los mismos.

Info

Publication number
MX2018005135A
MX2018005135A MX2018005135A MX2018005135A MX2018005135A MX 2018005135 A MX2018005135 A MX 2018005135A MX 2018005135 A MX2018005135 A MX 2018005135A MX 2018005135 A MX2018005135 A MX 2018005135A MX 2018005135 A MX2018005135 A MX 2018005135A
Authority
MX
Mexico
Prior art keywords
cgrp
bispecific antibodies
disease
psa
crohn
Prior art date
Application number
MX2018005135A
Other languages
English (en)
Inventor
Brautigam Beidler Catherine
Allan Barrett
Jan Benschop Robert
Lee Millican Rohn Jr
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2018005135A publication Critical patent/MX2018005135A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan anticuerpos biespecíficos que se unen al péptido relacionado con el gen de la calcitonina (CGRP) e interleucina-23 (lL-23) y se caracterizan por tener una alta afinidad y fuertes propiedades de neutralización simultánea tanto para CGRP como para lL-23. Los anticuerpos biespecíficos de la invención son útiles para tratar diversas enfermedades autoinmunes, incluyendo la enfermedad inflamatoria intestinal, tales como la enfermedad de Crohn y colitis ulcerosa, artritis psoriásica (PsA) y espondilitis anquilosante (AS).
MX2018005135A 2015-10-30 2015-10-30 Anticuerpos biespecificos anti-cgrp/anti-il-23 y usos de los mismos. MX2018005135A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/058362 WO2017074428A1 (en) 2015-10-30 2015-10-30 Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2018005135A true MX2018005135A (es) 2018-06-06

Family

ID=54477401

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005135A MX2018005135A (es) 2015-10-30 2015-10-30 Anticuerpos biespecificos anti-cgrp/anti-il-23 y usos de los mismos.

Country Status (12)

Country Link
US (1) US20180291093A1 (es)
EP (1) EP3368066A1 (es)
JP (1) JP6592600B2 (es)
KR (1) KR20180054851A (es)
CN (1) CN108135983A (es)
AU (1) AU2015413277A1 (es)
BR (1) BR112018007214A2 (es)
CA (1) CA3003243A1 (es)
EA (1) EA201890741A1 (es)
IL (1) IL258534A (es)
MX (1) MX2018005135A (es)
WO (1) WO2017074428A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
US12402610B2 (en) * 2018-11-09 2025-09-02 The Broad Institute, Inc. Methods and compositions for modulating innate lymphoid cell pathogenic effectors
US20230357419A1 (en) * 2022-05-04 2023-11-09 Washington University Methods for treating or preventing headache disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100135998A1 (en) * 2007-02-28 2010-06-03 Schering Corporation Combination therapy for treatment of immune disorders
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
ES2456296T3 (es) * 2008-03-27 2014-04-21 Zymogenetics, Inc. Composiciones y procedimientos para inhibir PDGFR beta y VEGF-A
JO3330B1 (ar) * 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
US8889130B2 (en) * 2011-02-08 2014-11-18 Abbvie Inc. Treatment of osteoarthritis and pain
EP2709662B1 (en) * 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
TWI636063B (zh) * 2013-03-08 2018-09-21 美國禮來大藥廠 結合ｉｌ－２３之抗體
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23

Also Published As

Publication number Publication date
EP3368066A1 (en) 2018-09-05
JP2019501114A (ja) 2019-01-17
KR20180054851A (ko) 2018-05-24
WO2017074428A1 (en) 2017-05-04
IL258534A (en) 2018-06-28
AU2015413277A1 (en) 2018-04-12
US20180291093A1 (en) 2018-10-11
CN108135983A (zh) 2018-06-08
EA201890741A1 (ru) 2018-10-31
CA3003243A1 (en) 2017-05-04
JP6592600B2 (ja) 2019-10-16
BR112018007214A2 (pt) 2018-10-16

Similar Documents

Publication Publication Date Title
ZA201706740B (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
ZA201708265B (en) Tigit-binding agents and uses thereof
EA033433B1 (ru) Антитела к tau и их применение
MX2015011957A (es) Anticuerpos biespecificos anti-tnf-anti-il-17.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EA201890756A1 (ru) Антитела, которые специфически связываются с tl1a
SG10201907161YA (en) Antibodies directed against lymphocyte activation gene 3 (lag-3)
TN2018000324A1 (en) ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123
TN2015000348A1 (en) Antibodies that bind il-23
JO3568B1 (ar) عوامل ربط cd123 واستخداماتها
MX2022006575A (es) Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.
PH12018500578A1 (en) Methods of treating inflammatory diseases
WO2017006052A3 (fr) UTILISATION DE FRAGMENTS Fc MODIFIÉS EN IMMUNOTHÉRAPIE
PH12019502298A1 (en) Monoclonal antibody to pd-l1
WO2016173605A8 (en) Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
WO2015187521A3 (en) Anti-blys antibodies
PH12018502275B1 (en) Interferon beta antibodies and uses thereof
EP3974451A3 (en) Methods of treating inflammatory diseases
MY197821A (en) Anti-il-22r antibodies
MX2018005135A (es) Anticuerpos biespecificos anti-cgrp/anti-il-23 y usos de los mismos.
JOP20200106A1 (ar) جسم مضاد أحادي النسيلة مضاد لـ il-5r?
EA201890549A1 (ru) Применение гидрофобно-ассоциирующих сополимеров в качестве связующих веществ для окомковывания металлосодержащих руд
MX2016012986A (es) Composiciones y metodos para identificar especies de ehrlichia.
BR112017022086A2 (pt) anticorpos dirigidos contra o receptor de interleucina 36 (il-36r)